Multivariate regression analyses of data from a randomised, double-blind, placebo-controlled study confirm quality of life benefit of epoetin alfa in patients receiving non-platinum chemotherapy
Open Access
- 26 November 2002
- journal article
- clinical trial
- Published by Springer Nature in British Journal of Cancer
- Vol. 87 (12), 1341-1353
- https://doi.org/10.1038/sj.bjc.6600657
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Human recombinant erythropoietin and quality of life: a wonder drug or something to wonder about?The Lancet Oncology, 2002
- Predicting cancer-associated anaemia in patients receiving non-platinum chemotherapy: results of a retrospective surveyEuropean Journal Of Cancer, 2001
- Effects of epoetin alfa on the central nervous systemSeminars in Oncology, 2001
- Epoetin alfa overcomes much of the QOL deficit seen in anaemic cancer patientsEuropean Journal Of Cancer, 2001
- Fatigue in cancer patientsCurrent Opinion in Oncology, 1999
- Normalizing hematocrit in dialysis patients improves brain functionAmerican Journal of Kidney Diseases, 1999
- EditorialEuropean Journal Of Cancer, 1998
- 79 Correlation of quality of life (QOL) with survival, treatment response, and anemia in patients with advanced non-small cell lung cancer (NSCLC) treated with carboplatin and paclitaxelLung Cancer, 1997
- rHuEPO treatment improves brain and cognitive function of anemic dialysis patientsKidney International, 1991
- A sharper Bonferroni procedure for multiple tests of significanceBiometrika, 1988